NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

RadNet, Inc. (RDNT) Stock Analysis

RadNet, Inc. (RDNT) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

RDNT

$73.71

−$0.91 (−1.22%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RDNT with… →

RDNT Key Statistics

As of Sep 4, 2026
Trading
Open
$73.82
Previous Close
$74.62
Day's Range
73.36–74.70
52-Week Range
50.82–85.84
Volume
502.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.40
Valuation
Market Cap
$5.80B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
83.13
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.96
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.26
Financials (FY)
Revenue (FY)
$2.04B+11.51%
Net Income (FY)
−$18.65M−767.81%
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.93%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
78.70M
1-Year Return
+1.95%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
826.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RDNT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.31%
2025+2.16%
2024+100.86%
2023+84.65%
2022−37.46%
2021+53.86%
2020−3.60%
2019+99.61%
2018+0.69%
2017+56.59%
2016 (partial year)+8.04%

As of September 4, 2026.

RDNT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.04B−$18.65M−0.9%
2024$1.83B$2.79M0.2%
2023$1.62B$3.04M0.2%
2022$1.43B$10.65M0.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.04B$235.49M$83.36M−$18.65M−0.9%
2024$1.83B$249.12M$111.28M$2.79M0.2%
2023$1.62B$221.39M$93.00M$3.04M0.2%
2022$1.43B$165.72M$49.84M$10.65M0.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RDNT Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricRDNTDiagnostics & Research medianvs median
P/S ratio2.564.9949% below
Profit margin−0.93%0.00%0.9 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

RadNet, Inc. (RDNT) carries a market capitalisation of $5.80B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 11,000.

The most recent close on file for RDNT is $73.71, dated September 4, 2026. That is −$0.91 (−1.22%) against the previous close. Over the past 52 weeks the price has ranged from $50.82 to $85.84. The latest close sits 45.04% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.04B. That is +11.51% against the prior fiscal year, when revenue was $1.83B. The same year closed with a net loss of $18.65M. The reported profit margin is −0.93%. That is 0.9 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −0.26.

Across the 4 fiscal years on file, revenue moves from $1.43B in 2022 to $2.04B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 83.13. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.96. The price-to-sales ratio is 2.56. On price-to-sales that is 48.77% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 1.4. Annualized volatility over the trailing 10 years is 48.41%. The trailing one-year price return is +1.95%. Across 10 years the annualized return works out at +26.54%.

Growth & Income

No dividend is on file for RDNT.

2026 is still running; the price is +3.31% year to date. Across the complete calendar years on file, 2024 returned +100.86% and 2022 returned −37.46%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

RadNet, Inc. (RDNT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
RadNet, Inc. RDNT $5.80B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. RadNet, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About RadNet, Inc.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Visit website →